Puma Biotechnology, Inc.
A biopharmaceutical company based in Los Angeles that develops and sells cancer treatments, best known for its breast-cancer drug Nerlynx, a pill given to adults with HER2-positive breast cancer to help stop the disease from returning. It was founded in 2010 by Alan Auerbach, the same entrepreneur behind the earlier Cougar Biotechnology, whose big-cat naming theme it kept: puma and cougar are simply two names for the same mountain lion, and the drug itself was licensed from Pfizer in 2011.
Granted 3.24M · Sold 354.9K
Granted 272.3K · Sold 100.2K
Granted 206.2K · Sold 67.4K
Granted 181.0K · Sold 60.3K
Granted 146.8K · Sold 23.8K
Granted 135.0K · Sold 49.0K
Granted 135.0K · Sold 44.2K
Granted 135.0K · Sold 132.5K
Granted 108.0K · Sold 39.1K
Granted 135.0K · Sold 103.5K
Granted 135.0K · Sold 110.9K
Granted 135.0K · Sold 135.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Auerbach Alan HPresident and CEO, Director, 10% owner · 34 transactions | +65.3% | 7.31M | 3.24M | — | 354.9K |
| Nougues Maximo FChief Financial Officer · 31 transactions | +253.4% | 240.0K | 272.3K | — | 100.2K |
| Hunt Douglas MSee Remarks · 31 transactions | +208.6% | 205.3K | 206.2K | — | 67.4K |
| Ludwig Jeffrey JeromeChief Commercial Officer · 12 transactions | +334.7% | 156.8Kas of Feb 2025 | 181.0K | — | 60.3K |
| Wong Alvin FChief Scientific Officer · 12 transactions | +14566.8% | 141.2Kas of Feb 2024 | 146.8K | — | 23.8K |
| Stuglik Brian MDirector · 10 transactions | +308.7% | 113.9K | 135.0K | — | 49.0K |
| Dorval AllisonDirector · 9 transactions | — | 90.8K | 135.0K | — | 44.2K |
| Miller Michael PatrickDirector · 11 transactions | +3.2% | 81.0K | 135.0K | — | 132.5K |
| Cesano AlessandraDirector · 6 transactions | — | 68.8K | 108.0K | — | 39.1K |
| Wilson Troy EdwardDirector · 10 transactions | +109.7% | 60.3K | 135.0K | — | 103.5K |
| Moyes Jay MDirector · 10 transactions | +70.6% | 58.3K | 135.0K | — | 110.9K |
| Senderowicz AdrianDirector · 10 transactions | -3.1% | 27.0K | 135.0K | — | 135.9K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -1.22M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.